Chou A C, Shih Y F, Ho T C, Lin L L
Department of Ophthalmology, National Taiwan University Hospital, Taipei, Republic of China.
J Ocul Pharmacol Ther. 1997 Feb;13(1):61-7. doi: 10.1089/jop.1997.13.61.
Twenty highly myopic children (> or = -6.0 D) were treated with 0.5% atropine eyedrops once per night. Twelve subjects were initially treated with a short-acting cycloplegic agent, tropicamide (0.5%) (Group A), and the other eight subjects did not receive any myopic therapy before atropine (Group B). These cases were followed for up to five years. In Group A, the mean myopic progression rate after 0.5% atropine treatment was -0.01 +/- 0.04 D/M (Diopter/Month), which was significantly lower than that of the period during tropicamide treatment (-0.12 +/- 0.09 D/M) (p < 0.05). In Group B, the mean myopic progression rate after atropine therapy was begun was -0.04 +/- 0.06 D/M, which was also significantly slower than that of non-medication, -0.14 +/- 0.07 D/M (p < 0.05). The results suggested that 0.5% atropine is effective for slowing down myopic progression, even in highly myopic children.
20名高度近视儿童(近视度数≥-6.0 D)每晚使用0.5%阿托品滴眼液治疗一次。12名受试者最初用短效睫状肌麻痹剂托吡卡胺(0.5%)治疗(A组),另外8名受试者在使用阿托品之前未接受任何近视治疗(B组)。对这些病例进行了长达五年的随访。在A组中,0.5%阿托品治疗后的平均近视进展率为-0.01±0.04 D/月,显著低于托吡卡胺治疗期间的近视进展率(-0.12±0.09 D/月)(p<0.05)。在B组中,开始阿托品治疗后的平均近视进展率为-0.04±0.06 D/月,也显著慢于未用药时的-0.14±0.07 D/月(p<0.05)。结果表明,0.5%阿托品即使对高度近视儿童也能有效减缓近视进展。